Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000929638-21-000414
Filing Date
2021-02-26
Accepted
2021-02-26 17:02:10
Documents
2
Group Members
JEFF EASTONLIND GLOBAL PARTNERS LLC

Document Format Files

Seq Description Document Type Size
1 sc13g.htm SC 13G 72631
2 JOINT FILING AGREEMENT exhibit99-1.htm EX-99.1 7778
  Complete submission text file 0000929638-21-000414.txt   82073
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Subject) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: SC 13G | Act: 34 | File No.: 005-92289 | Film No.: 21690623
SIC: 2834 Pharmaceutical Preparations

Mailing Address 444 MADISON AVE, FLOOR 41 NEW YORK NY 10022
Business Address 444 MADISON AVE, FLOOR 41 NEW YORK NY 10022 646-395-3931
Lind Global Macro Fund LP (Filed by) CIK: 0001773156 (see all company filings)

EIN.: 830854952 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G